Imprimis Pharmaceuticals (NASDAQ:IMMY) Earns News Impact Score of 0.23
Headlines about Imprimis Pharmaceuticals (NASDAQ:IMMY) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.0174079005638 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s rankings:
- Imprimis Pharma (IMMY) Issues Statement on Curcumin Emulsion FDA MedWatch Notice (streetinsider.com)
- Flipkart will sell refurbished smartphones at discounted prices by Diwali (ismboard.com)
- Imprimis Stock Down in Response to FDA Inquiry for Curcumin Emulsion (biospace.com)
- Imprimis Statement Regarding Curcumin Emulsion FDA MedWatch Notice (finance.yahoo.com)
- FDA Links Naturopathic Turmeric Death To Contaminated Product (finance.yahoo.com)
Shares of Imprimis Pharmaceuticals (IMMY) traded up 11.50% on Tuesday, hitting $2.23. The company’s stock had a trading volume of 301,183 shares. Imprimis Pharmaceuticals has a 1-year low of $1.65 and a 1-year high of $4.69. The company has a 50 day moving average of $2.99 and a 200 day moving average of $3.14. The firm’s market cap is $44.74 million.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last posted its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.07. The company had revenue of $6.10 million for the quarter, compared to the consensus estimate of $6.50 million. Imprimis Pharmaceuticals had a negative net margin of 82.11% and a negative return on equity of 341.80%. Equities analysts forecast that Imprimis Pharmaceuticals will post ($0.86) EPS for the current year.
Several brokerages have weighed in on IMMY. Zacks Investment Research upgraded Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. ValuEngine upgraded Imprimis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd.
ILLEGAL ACTIVITY WARNING: “Imprimis Pharmaceuticals (NASDAQ:IMMY) Earns News Impact Score of 0.23” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/08/imprimis-pharmaceuticals-nasdaqimmy-earns-news-impact-score-of-0-23.html.
In other news, Director Robert J. Kammer sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $3.05, for a total transaction of $30,500.00. Following the completion of the transaction, the director now directly owns 1,059,827 shares of the company’s stock, valued at $3,232,472.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.55% of the stock is currently owned by corporate insiders.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Receive News & Ratings for Imprimis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.